■ Market Review

On Oct. 25, Hanmi Pharmaceutical (128940) declined 2.88% to 404,000 won (US$355.13). It had declined 33.33% through the past month. Standard deviation, the volatility index for stock price, was 2.3% over the same period of time over one month.

Compared with its close competitors within the same industry, KOSPI, the monthly volatility of Hanmi Pharmaceutical was not so high, the earnings rate for one month was also the lowest with decline of stock price. Over the recent month, the return-on-risk, the return on investment with consideration about risk, was -14.4%. As high volatility and a bearish stock price trend, the return-on-risk was poor, compared with its peer group. Moreover, compared with the KOSPI industry, the return-on-risk is below the industrial mean, -1.6, and thus the industrial comparison performance was not so good.

Comparing industry to the market, the KOSPI industry including Hanmi Pharmaceutical records higher volatility but lower earning rate than medical supplies. Even though the earning rate of the industry is negative, the industry was more satisfactory than the market.

■ Earnings & Valuation

HanmiPharm(128940): 2Q(Apr ~ June) of 2016 Earnings (reported at July 28. 2016)

Compared with four close competitors with similar market capitalization within its industry, while Hanmi Pharmaceutical's P/E ratio, a price-paid ratio of annual net income, is relatively lower value, its P/B ratio, a financial ratio of a company's book value, is relatively higher value.

Close Compatitors ROE

■ Investor Group

Cumulated shareholdings per investor group (1Mo)  

* Other Investor groups, included as "other corporations", are considered as "Individuals".